Skip to main content
OpenTrials
Recruiting

NCT Number: NCT07084545

Evaluation of Cataract Surgery Outcomes in Patients With Prior Laser Vision Correction Implanted With the CT LUCIA Lens

This is a prospective, Phase IV, post-approval observational study evaluating postoperative outcomes in patients with a history of myopic corneal laser vision correction (LVC) undergoing bilateral cataract surgery with implantation of the CT LUCIA 621P intraocular lens (IOL). Up to 30 subjects (60 eyes) will be enrolled across up to three U.S. investigational sites. The study will assess visual and refractive outcomes, including biometry, manifest refraction, and patient-reported visual function over a 3-month follow-up period.

Recruiting

Interested in participating?

Request Info

Key information

Age range

18 year and older

Sex eligibility

All sexes

Study type

Observational

Primary location

Berkeley Eye Center, Sugar Land, Texas, United States

Loading trial locations.

Who can participate

Healthy volunteers accepted: No

Only the study team can determine whether someone qualifies for participation.

Inclusion criteria

  • Be at least 18 years of age or older.
  • Previous cornea LVC surgery performed at least 1 year before the implantation of the CT LUCIA 621P IOL, such as Laser-Assisted Intrastromal Keratomileusis (LASIK), Laser-Assisted Subepithelial Keratectomy (LASEK), Photorefractive Keratectomy (PRK) or Small Incision Lenticule Extraction (SMILE) for mild to moderate myopia, with or without astigmatism (up to, but not including, -6.0 D sphere in any meridian for myopic ablations.
  • Presenting for planned bilateral cataract extraction with in-the-bag posterior chamber IOL implantation, via phacoemulsification with or without femtosecond laser assisted cataract surgery (FLACS). Astigmatism management techniques, such as Astigmatic Keratotomy (AK), may be utilized during cataract surgery to target a predicted postoperative cylinder less than 0.75 D.
  • Clear intraocular media other than cataract (i.e., no hyphema, vitreous hemorrhage).
  • No visual acuity limiting corneal or retinal pathologies.
  • Able to and having provided written informed consent and a signed Health Insurance Portability and Accountability Act (HIPAA) form.
  • Availability, willingness, ability, and sufficient cognitive awareness to comply with study examination procedures and the schedule for study visits and evaluations.

Exclusion criteria

  • Implantation of an IOL other than the CT LUCIA 621P in one or both eyes.
  • Eyes with preoperative anterior corneal astigmatism of ΔTK ≥1.00 D as measured by the IOLMaster 700 or with greater than 0.75 D predicted post-operative astigmatism at the spectacle plane.
  • Visual field loss which has an impact on visual acuity.
  • Subjects with diagnosed degenerative visual disorders (e.g., macular degeneration or other retinal disorders) that would confound visual acuity measurement.
  • Subjects with surgical complications in whom a CT LUCIA 621P IOL cannot be implanted in either eye.
  • Eyes with irregular corneal astigmatism, epithelial basement membrane dystrophy, chronic dry eye requiring continual treatment, underwent more than one LVC procedure in one or both eyes, or complications from the previous LVC which required additional surgical intervention.
  • Subjects with planned ocular surgery during the study (except Nd:YAG capsulotomy is permitted).
  • History of acute or chronic disease, pathology, illness, or ocular trauma that would, in the opinion of the investigator, confound results.
  • Current diagnosis of macular degeneration, cystoid macular edema, proliferative diabetic retinopathy, amblyopia, or other chronic ocular conditions that would confound the study results.
  • A current diagnosis of moderate or severe glaucoma.
  • Patients with strabismus, forme fruste keratoconus, keratoconus or other corneal pathologies that would confound visual acuity measurement.
  • Previous radial keratotomy (RK).
  • Previous corneal keratoplasty (e.g., corneal transplant, Descemet's stripping automated endothelial keratoplasty (DSAEK), lamellar keratoplasty).
  • Previous anterior or posterior chamber surgery (e.g., vitrectomy, laser iridotomy).
  • Pupil abnormalities (non-reactive, tonic pupils, abnormally shaped pupils, or pupils that do not dilate under mesopic/scotopic conditions).
  • Capsular or zonular abnormalities or other conditions that may affect the postoperative centration or tilt of the lens (e.g., pseudoexfoliation syndrome).
  • Usage of contact lenses during study participation.
  • Concurrent participation in another device investigation.

Treatment and study plan

CT LUCIA 621P Intraocular Lens Implantation

Device

The intervention consists of bilateral implantation of the CT LUCIA 621P intraocular lens (IOL) during routine cataract surgery in patients with a history of myopic corneal laser vision correction. The CT LUCIA 621P IOL is an approved, single-piece, hydrophobic acrylic lens designed to provide improved visual quality and refractive stability. Implantation is performed following each investigator's standard surgical procedures, including preoperative preparation, operative technique, and postoperative care. IOL power calculation uses the ZEISS Cataract Workflow platform with the VERACITY system and Barrett True-K with TK formula, incorporating the VERION Optical Coherence (VOC) technology.

Primary outcomes

  1. Mean Prediction Error (PE)

    Time frame: 3 months postoperatively

    The average difference between postoperative manifest refraction spherical equivalent (MRSE) and predicted MRSE based on IOLMaster 700 with Barrett True-K with TK formula.

  2. Median Prediction Error (PE)

    Time frame: 3 months postoperatively

    The median difference between postoperative MRSE and predicted MRSE based on IOLMaster 700 with Barrett True-K with TK formula.

  3. Absolute Prediction Error (PE)

    Time frame: 3 months postoperatively

    The absolute value of the difference between postoperative MRSE and predicted MRSE based on IOLMaster 700 with Barrett True-K with TK formula.

  4. Percentage of Eyes Within ±0.25 D of Predicted MRSE

    Time frame: 3 months postoperatively

    The proportion of eyes achieving postoperative MRSE within ±0.25 D of the predicted MRSE based on IOLMaster 700 with Barrett True-K with TK formula.

  5. Percentage of Eyes Within ±0.50 D of Predicted MRSE

    Time frame: 3 months postoperatively

    The proportion of eyes achieving postoperative MRSE within ±0.50 D of the predicted MRSE based on IOLMaster 700 with Barrett True-K with TK formula.

  6. Percentage of Eyes Within ±1.00 D of Predicted MRSE

    Time frame: 3 months postoperatively

    The proportion of eyes achieving postoperative MRSE within ±1.00 D of the predicted MRSE based on IOLMaster 700 with Barrett True-K with TK formula.

Secondary outcomes

  1. Corrected Distance Visual Acuity (CDVA)

    Time frame: 3 months postoperatively

    Monocular and binocular postoperative corrected distance visual acuity measured by standard methods.

  2. Uncorrected Distance Visual Acuity (UDVA)

    Time frame: 3 months postoperatively

    Monocular and binocular postoperative uncorrected distance visual acuity.

Study contacts

Contact information is provided by the study sponsor or research team.

Henry Heering

CONTACT

[email protected]

949-293-0520

Sponsors and collaborators

Lead sponsor

Carl Zeiss Meditec AG

Industry

Registry information

Official study title

EPIC: Evaluation of the Postoperative Cataract Surgery Outcomes in Patients With Prior Corneal Laser Vision Correction Implanted With the CT LUCIA Intraocular Lens Protocol GPAS-SAS-023-4

Important dates

Study start
2025
Primary completion
2026
Study completion
2026
First posted
Jul 24, 2025
Registry last updated
Jul 24, 2025

OpenTrials presents study information sourced from ClinicalTrials.gov. The official registry record should be consulted for the latest information.

View the official ClinicalTrials.gov record (opens in a new tab)

This listing is for discovery and informational purposes only. It is not medical advice, does not guarantee that a study is recruiting, and does not determine eligibility. Contact the study team and a qualified healthcare professional when considering participation.